d&#x27;Andrea G

Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.

Martiadis V, Raffone F, Atripaldi D +8

Europe PMC2026

Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole.

d'Andrea G, Cavallotto C, Susini O +10

Europe PMC2026

ArticlePsychedelics

Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.

Pettorruso M, d'Andrea G, Inserra A +12

Europe PMC2026

Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.

d'Andrea G, Chiappini S, Ciavoni L +13

Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group.

d'Andrea G, Cavallotto C, Pettorruso M +25

Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience).

Di Nicola M, Pepe M, d'Andrea G +26

Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.

Rosso G, d'Andrea G, Barlati S +15

Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.

d'Andrea G, Miuli A, Pettorruso M +12

Europe PMC2024

ArticlePsilocybin

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Wong S, Kwan ATH, Teopiz KM +8

Europe PMC2024

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

d'Andrea G, Pettorruso M, Di Lorenzo G +16

Europe PMC2024

Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression.

d'Andrea G, Pettorruso M, Rhee TG +3

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).

Pettorruso M, Guidotti R, d'Andrea G +25

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.

d'Andrea G, Chiappini S, McIntyre RS +12

The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review.

Jawad MY, Qasim S, Ni M +8

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.

Chiappini S, d'Andrea G, De Filippis S +10

Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?

d'Andrea G, Pettorruso M, Lorenzo GD +3

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.

Martinotti G, Dell'Osso B, Di Lorenzo G +23